Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsNASALGeneric

DIAPID

LYPRESSIN

Standard Dose
0.185MG/ML
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued

Key Takeaways

  • Primary indication: Marketing status: Discontinued
  • Approval overview DIAPID is listed in Drugs@FDA under application 016755 (NDA).
  • Marketing status: Discontinued Active ingredient LYPRESSIN Form and strength SOLUTION;NASAL - 0.185MG/ML Sponsor NOVARTIS Submission history See approval history documents.

Structured Monograph

Clinical summary

Approval overview DIAPID is listed in Drugs@FDA under application 016755 (NDA). Marketing status: Discontinued Active ingredient LYPRESSIN Form and strength SOLUTION;NASAL - 0.185MG/ML Sponsor NOVARTIS Submission history See approval history documents.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.